ClinicaliQ Trial Snapshot
- International Registry for Men With Advanced Prostate Cancer (IRONMAN) — Recruiting • Oncology • NCT03151629.
- What is being tested: IRONMAN is establishing an international prospective registry of ≥5,000 men with advanced prostate cancer, including metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic/metastatic castration-resistant prostate cancer (M0/M1 CRPC), to collect real-world clinical outcomes data.
- Patient eligibility overview: The registry enrolls men diagnosed with advanced prostate cancer across international centres, spanning multiple disease states from hormone-sensitive to castration-resistant disease with varying metastatic burden.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, Spain, South Africa, Sweden, Switzerland, the United Kingdom (UK), and the United States (US). Target accrual number and number of participating sites are subject to change based…
Eligibility Snapshot
- • Willing and able to provide written informed consent and privacy authorization for the release of personal health information. NOTE: Privacy authorization may be either included in the informed consent or obtained separately. * Males 21 years of age and above * Histological or cytological confirmed prostate adenocarcinoma from TRUS biopsy, radical prostatectomy or TURP Or Documented histopathology or cytopathology of prostate adenocarcinoma from a biopsy of a metastatic site Or Metastatic disease typical of prostate cancer (i.e., involving bone or pelvic lymph nodes or para-aortic lymph nodes) AND a serum concentration of PSA >20ng/mL at the time of initial prostate cancer diagnosis * No previous diagnosis of a second, non-prostate malignancy that requires additional systemic therapy except cancer in situ of bladder and basal cell cancer of skin
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.